Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alright, investors! We’ve reached the midpoint of the week but there’s no time to start slacking off just yet! Instead, get ready to look over the biggest pre-market movers for Wednesday as we prepare for anot...
Alterity to present at the 7th International Congress of Multiple System Atrophy PR Newswire MELBOURNE, Australia and SAN FRANCISCO , Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will pres...
Alterity Therapeutics Ltd (ATHE) Q2 2021 Earnings Conference Call February 25, 2021, 17:00 ET Company Participants David Stamler - CEO, Chief Medical Officer & SVP, Clinical Development Kathryn Andrews - CFO Conference Call Participants Presentation Operator Good morning, and welcome to t...
Alterity Therapeutics (ATHE): 1H GAAP EPS of -A$0.65.Revenue of A$1.93M (+3.2% Y/Y)Press Release For further details see: Alterity Therapeutics reports 1H results
Alterity Therapeutics shares jump ([[ATHE]] +18.7%) after it announces the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's disease ((PD)) based on imaging of brain iron.The funding of $4...
Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials PR Newswire NEW YORK , Feb. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the ...
Alterity Therapeutics ([[ATHE]] +1.8%) announces the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately.Dr Stamler joined Alterity Therapeutics in June 2017 as Chief Medical Officer and Senior Vice President Clinical Development; and has significant ph...
Dr David Stamler Appointed CEO PR Newswire MELBOURNE, Australia , Jan. 7, 2021 /PRNewswire/ -- The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of Dr David Stamler to the rol...
Alterity and UniQuest partner to reverse bacterial resistance to antibiotics New commercial opportunity for PBT2 PR Newswire MELBOURNE, Australia , Dec. 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has ...
Titan Pharmaceuticals (TTNP) -15%.Tuniu TOUR -15% on Q3 earnings release.Medigus MDGS -15% on appointment of new finance chief at MedigusECMOHO MOHO -14% on Q3 earnings release.Minerva Neurosciences (NERV) -14% after announcing outcome of Type C meeting with...
News, Short Squeeze, Breakout and More Instantly...
Alterity Therapeutics Limited Company Name:
ATHE Stock Symbol:
NYSE Market:
Alterity Therapeutics Limited Website:
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings ...
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings ...
MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today an...